Company site in Germany is the BioPharmaPark in Dessau-Rosslau. In the United States, IDT Corporation operates a production site for clinical test samples in Rockville, Maryland.
Production, Research & Development
IDT Biologika’s significant growth was fueled by the high demand for new vaccines to combat diseases around the globe. The company achieved sales of 240.9 million euros for fiscal year 2017 (preliminary figures). IDT annually invests around six percent of its revenue in research and development of its own proprietary products. In 2017 IDT employed approximately 1,915 people worldwide.
As a global manufacturer, IDT Biologika undergoes regular inspections by clients and independent regulatory agencies, such as the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA). IDT Biologika’s advanced production system positions the company among the world’s leading vaccine manufacturing corporations. Pioneering technologies for the production of new vaccines and pharmaceuticals underscores IDT’s commitment to set standards for pharmaceutical production, both now and in the future. IDT Biologika’s focus on customers and operational excellence has earned the company many international awards.
Hugo Junkers Award
CMO Leadership Award
Facility of the Year Award
Customer Service Leadership Award
IDT Biologika is a member of the Klocke Group. Klocke Group companies are specialized in contract production and packaging of medications, vaccines and cosmetic products. A traditional, family-owned company, the Klocke Group employs a workforce of more than 2,000 people in Europe and the U.S. The group offers comprehensive services for the manufacture and packaging of pharmaceutical products at its six production facilities.
For more information about the Klocke Group, visit: www.klocke.com